Lipid Management in 2015: Risk & Controversies

Slides:



Advertisements
Similar presentations
TREATING LIPIDS FOR PREVENTION OF CAD : HOW AGGRESSIVE SHOULD WE BE? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration.
Advertisements

Cardiovascular Risk Assessment
Summary Prepared by Melvyn Rubenfire, MD
Paul Muntner, Lisandro D Colantonio, Mary Cushman, David C Goff Jr
Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.
Robert M. Guthrie, MD Professor of Emergency Medicine
What is cholesterol? Cholesterol is a waxy, fatlike substance that is naturally present in cell walls or membranes everywhere in the body. Your body uses.
Am I At Risk? If you have any of these risk factors, you are at risk for heart disease. Controllable Risk Factors Uncontrollable Risk Factors High Cholesterol.
Controversies in Myocardial Perfusion Imaging Thomas H. Hauser, MD, MMSc, FACC Director of Nuclear Cardiology Beth Israel Deaconess Medical Center Instructor.
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol VA-HIT Rubins, HB, et.
Peripheral Arterial Disease >Increasing Awareness >What is PAD >Risk factors >Symptoms of PAD >Screening & Treatment Options.
Plasma Lipids at diagnosis of Type 2 Diabetes UKPDS study group, Diabetes Care 1997; 20: (55)1.1 (43) 1.0 (39)HDL-C mmol/l (mg/dl) 1.8 (159)
©PPRNet 2014 Impact of Patient Engagement on Treatment Decisions and Patient-Centered Outcomes in the Implementation of New Guidelines for the Treatment.
Metabolic & Endocrine Disease Summit Dyslipidemia and Current Guidleines for Lipid Management Thursday July 28, 2011 Orlando, FL Joyce L. Ross, MSN, CRNP,
By Apurva D. Shah, FACC Northside Heart and Vascular Institute.
Secretory Phospholipase A2: A New Risk Factor and Soon a New Target of Therapy Rabih R. Azar, MD, MSc, FACC Associate Professor of Medicine Division of.
Morteza Naghavi, M.D. Society for Heart Attack Prevention and Eradication (SHAPE) Detection and Treatment of Asymptomatic Atherosclerosis for Primary Prevention.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
CVD risk estimation and prevention: An overview of SIGN 97.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Slide Source: Lipids Online Slide Library Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT): Design Cannon CP.
Cholesterol quintile (mg/dL)
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Morteza Naghavi, M.D. Founder Society for Heart Attack Prevention and Eradication (SHAPE) SHAPE Guidelines Prevention of Fatal Cardiovascular Events (Heart.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
FATS4 Linking cases to the guideline Jane S Skinner Consultant Community Cardiologist.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.
© Continuing Medical Implementation ® …...bridging the care gap Geriovascular Prevention Optimizing Prevention of Cardiovascular Disease in the Elderly.
Neal S. Perlmutter, MD, FACC Overlake Medical Clinics Cardiology
Cholesterol guidelines
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Copyright © 2015 by the American Osteopathic Association.
Redefining Quality Care in T2DM Patients with CV Disease
Safi U. Khan MD; John Pamula MD
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
Cholesterol practice questions
Heart Health & Diabetes
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Neil J. Stone et al. JACC 2014;63:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Case 1: A 73-year-old white female with carotid disease
Martin Bødtker Mortensen, and Erling Falk JACC 2018;71:85-94
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Rational Order of Laboratory Tests in Cardiovascular Diseases
Contemporary Evidence-Based Guidelines
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Cardiovascular Disease in Women Module III: Risk Assessment Tool
Train-the-Trainer Cases
Preventative Cardiology
Train-the-Trainer Cases
Case 1: A 78-year-old white female with hypertension and hyperlipidemia Discussion Points: In that this patient has documented atherosclerotic vascular.
Train-the-Trainer Cases
Putting Your Skills to the Test
Case—History 75 year old woman referred for statin intolerance in 2016
Section 6: Update on lipid treatment guidelines
Presentation transcript:

Lipid Management in 2015: Risk & Controversies Michael Miller, MD R. Michael Benitez, MD

2013 ACC/AHA Guidelines Emphasis on statins as first-line therapy due to strong body of supporting evidence Focus on ‘appropriate intensity’ statin therapy in 3 groups ‘most likely to benefit’ 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Stone NJ, et al. Circulation 2013; JACC 2013

#1 - Clinical Atherosclerotic CVD History of CAD, MI, stable/unstable angina Coronary or other arterial revascularization CVA / TIA Peripheral arterial disease

#2 - LDL > 190 mg/dl Targeting familial hypercholesterolemia

#3 - Diabetic, age 40-75, LDL 70-189 Calculate 10 year risk of atherosclerotic CVD If Risk > 7.5% High-Intensity statin If Risk < 7.5%, moderate-intensity statin Lowers LDL 30-50% Atorva 10-20, rosuva 5-10, simva 20-40, prava 40-80, lova 40, pitava 2 – 4

10 Year ASCVD Risk: Pooled Cohort Equation Demographics Age (40-79) Gender Race History HTN DM Tobacco Measurements Tchol HDL Systolic BP

Estimated 10 year risk >7.5% The guidelines state that the risk estimator does not, and should not determine which patients receive statins Statin use should be determined after a ‘detailed risk discussion’ between patient and physician

Case 1 Tom is a 55 year old African American man He had a NSTEMI at age 50, with subsequent PCI of the LAD. He is on atorvastatin 80 mg/daily, along with aspirin, beta-blocker and ACE-i.

“Should I get my cholesterol checked?”

Tom’s labs TChol - 170 mg/dl Triglycerides - 140 mg/dl HDL Chol - 42 mg/dl LDL Chol - 90 mg/dl

Questions Should we still follow levels? How often should we follow levels? The current guidelines are very focused on statin therapy . . . What is the role of non-statin therapy for elevated LDL cholesterol?

Case 2 Tom’s older brother, aged 60, comes to see you. He had CABG at age 52, is a never- smoker, but has hypertension and type II diabetes, with a hemoglobin A1c of 7%. He shops with Tom, and they are both on Atorvastatin 80 mg daily. He is on no other lipid lowering medicine.

His cholesterol values: TChol - 164 mg/dl HDL Chol - 28 mg/dl LDL Chol - 70 mg/dl Triglycerides (fasting) - 280 mg/dl

Questions? Should he be treated with another agent for his elevated triglycerides? Should he receive any treatment targeted towards the low HDL cholesterol?

Case 3 Tom’s younger brother, age 50, also comes to see you. He is asymptomatic and has no known history of CAD, but he is worried that both of this older brothers had serious heart disease at about his age. He is a ‘never-smoker’, and is not hypertensive or diabetic. Tchol 220 / HDL 44 / SBP 132 mm Hg

Questions? How do we account for FAMILY HISTORY under the new guidelines? Should he be treated? What is the role of further testing? Coronary calcium scoring? Hi-sensitivity CRP?

He undergoes Coronary Calcium CT scoring; Agatston score of 28, all RCA

Questions? Does this establish him as having CAD? Should he be treated with statin? Hi dose? Moderate dose? (what should the target of treatment be - and how should this be followed?)

All in the Family Tom’s mother comes to see you. She has no history of CAD. She is hypertensive, not diabetic, has never smoked and is not symptomatic. She is 80 years old.

Questions? What is the role of statin therapy in the elderly ... for Primary Prevention? for Secondary Prevention?

How Low Should We Go? 53 yo Woman with newly diagnosed CAD Prior to statin: TC=86 TG= 27 HDL= 35 LDL= 46 She was placed on Atorvastatin 80 mg w/o symptoms. Do you continue same or modify regimen?